Healthcare provider profile · identity verified

Sandra Ivette Vazquez, M.D.

Internal Medicine · CAYEY, PR · NPI 1265521355

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	769	134
Losartan Potassium	Losartan Potassium	632	98
Metformin Hcl	Metformin Hcl	611	94
Gabapentin	Gabapentin	575	94
Atorvastatin Calcium	Atorvastatin Calcium	496	88
Synthroid	Levothyroxine Sodium	478	85
Famotidine	Famotidine	460	81
Metoprolol Succinate	Metoprolol Succinate	440	77
Simvastatin	Simvastatin	427	71
Lisinopril	Lisinopril	339	63
Alendronate Sodium	Alendronate Sodium	328	63
Amlodipine Besylate	Amlodipine Besylate	328	57
Omeprazole	Omeprazole	325	55
Pantoprazole Sodium	Pantoprazole Sodium	307	49
Ezetimibe	Ezetimibe	288	59
Montelukast Sodium	Montelukast Sodium	221	35
Pentoxifylline	Pentoxifylline	211	38
Januvia	Sitagliptin Phosphate	203	33
Hydrochlorothiazide	Hydrochlorothiazide	190	30
Fenofibrate	Fenofibrate	157	25
Albuterol Sulfate Hfa	Albuterol Sulfate	146	31
Levothyroxine Sodium	Levothyroxine Sodium	146	28
Fenofibrate	Fenofibrate Nanocrystallized	145	25
Glipizide	Glipizide	139	17
Diclofenac Sodium	Diclofenac Sodium	133	39
Fluticasone Propionate	Fluticasone Propionate	127	32
Irbesartan	Irbesartan	124	24
Tamsulosin Hcl	Tamsulosin Hcl	118	21
Nifedipine Er	Nifedipine	116	19
Clopidogrel	Clopidogrel Bisulfate	114	20
Farxiga	Dapagliflozin Propanediol	90	16
Glimepiride	Glimepiride	86	18
Sertraline Hcl	Sertraline Hcl	84	15
Furosemide	Furosemide	82	16
Nabumetone	Nabumetone	77	20
Carvedilol	Carvedilol	76	14
Latanoprost	Latanoprost	73	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	73	12
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	65	12
Naproxen	Naproxen	64	21
Clonidine Hcl	Clonidine Hcl	54	suppressed
Enalapril Maleate	Enalapril Maleate	52	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	50	suppressed
Hydralazine Hcl	Hydralazine Hcl	48	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	47	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	46	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	46	31
Donepezil Hcl	Donepezil Hcl	46	suppressed
Duloxetine Hcl	Duloxetine Hcl	45	suppressed
Sucralfate	Sucralfate	45	suppressed
Jardiance	Empagliflozin	44	suppressed
Atenolol	Atenolol	43	suppressed
Ibandronate Sodium	Ibandronate Sodium	43	suppressed
Spironolactone	Spironolactone	41	suppressed
Baclofen	Baclofen	38	23
Xarelto	Rivaroxaban	38	suppressed
Nitroglycerin	Nitroglycerin	36	suppressed
Pravastatin Sodium	Pravastatin Sodium	36	suppressed
Methotrexate	Methotrexate Sodium	35	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	34	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	32	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	31	suppressed
Levetiracetam	Levetiracetam	31	suppressed
Divalproex Sodium	Divalproex Sodium	30	suppressed
Eliquis	Apixaban	30	suppressed
Finasteride	Finasteride	30	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	28	suppressed
Meloxicam	Meloxicam	27	15
Methylprednisolone	Methylprednisolone	27	23
Allopurinol	Allopurinol	25	suppressed
Diclofenac Potassium	Diclofenac Potassium	24	suppressed
Meclizine Hcl	Meclizine Hcl	24	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	23	20
Humulin N	Insulin Nph Human Isophane	23	suppressed
Anastrozole	Anastrozole	22	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	22	suppressed
Lansoprazole	Lansoprazole	22	suppressed
Prednisone	Prednisone	22	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	21	suppressed
Memantine Hcl	Memantine Hcl	21	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Insulin Glargine	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Timolol Maleate	Timolol Maleate	20	suppressed
Sulindac	Sulindac	19	suppressed
Cilostazol	Cilostazol	18	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	18	suppressed
Metformin Hcl Er	Metformin Hcl	18	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Valsartan	Valsartan	17	suppressed
Verapamil Sr	Verapamil Hcl	17	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	16	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	16	suppressed
Ibuprofen	Ibuprofen	16	suppressed
Carbamazepine Er	Carbamazepine	15	suppressed
Clotrimazole	Clotrimazole	15	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Phenobarbital	Phenobarbital	15	suppressed
Trijardy Xr	Empaglifloz/Linaglip/Metformin	15	suppressed
Lactulose	Lactulose	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Estradiol	Estradiol	13	suppressed
Sildenafil Citrate	Sildenafil Citrate	13	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	12	suppressed
Etodolac	Etodolac	12	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	12	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	12	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	12	suppressed
Verapamil Hcl	Verapamil Hcl	12	suppressed
Azithromycin	Azithromycin	11	suppressed
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	11	suppressed
Folic Acid	Folic Acid	11	suppressed
Humalog	Insulin Lispro	11	suppressed
Isosorbide Mononitrate	Isosorbide Mononitrate	11	suppressed
Levoxyl	Levothyroxine Sodium	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error